Analysis of blood-based liquid biopsies in prostate cancer. Examples of...
Analysis of blood-based liquid biopsies in prostate cancer. Examples of molecular analyses enabled by the isolation of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and tumor-derived exosomes, are illustrated. Abbreviations: mCRPC: metastatic castration-resistant prostate cancer; cfDNA: cell-free circulating DNA.

Image source: Bonfil RD, Al-Eyd G, Oncoscience 2023 (CC BY 4.0)

News • CTC, ctDNA and exosomes in PCa management

Prostate cancer: Blood-based liquid biopsies yield valuable information

During the last decade, blood sampling of cancer patients aimed at analyzing the presence of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic growths emerged as an alternative to traditional tissue biopsies.

The advent of this minimally invasive approach, known as blood-based liquid biopsy, began to play a pivotal role in the management of diverse cancers, establishing itself as a vital component of precision medicine. In the new paper, published in Oncoscience, researchers R. Daniel Bonfil and Ghaith Al-Eyd from Nova Southeastern University discuss three blood-based liquid biopsies, namely circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and tumor-derived exosomes, as they relate to prostate cancer (PCa) management. “In this research perspective, we present a comprehensive overview of the recent advances related to the clinical significance of blood-based liquid biopsies in PCa, with a primary emphasis placed on key biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes.”

With the assistance of artificial intelligence based on pre-established parameters, the utilization of blood-based liquid biopsies will soon enhance the stratification of PCa patients and facilitate timely therapeutic decision making

R. Daniel Bonfil, Ghaith Al-Eyd

The advances achieved in the molecular characterization of these types of liquid biopsies and their potential to predict recurrence, improve responses to certain treatments, and evaluate prognosis, in PCa patients, are highlighted herein. While there is currently full clinical validation for only one CTC-based and one ctDNA-based liquid biopsy for patients with metastatic castration-resistant PCa, the adoption of additional methods is anticipated as they undergo standardization and achieve analytical and clinical validation. Advantages and disadvantages of different blood-based liquid biopsy approaches in the context of PCa are outlined in this paper, while also considering potential synergies through combinatory strategies. “We anticipate that, with the assistance of artificial intelligence based on pre-established parameters, the utilization of blood-based liquid biopsies will soon enhance the stratification of PCa patients and facilitate timely therapeutic decision making.” 


Source: Impact Journals, LLC

11.12.2023

Related articles

Photo

News • Circulating tumor extracellular vesicles

Metastatic prostate cancer: better monitoring with new liquid biopsy method

A new study shows that extracellular vesicles shed by prostate cancer cells contain tumor-derived material that can be used as biomarkers of therapy response and resistance in metastatic disease.

Photo

News • Urine-based diagnostics

New prostate cancer test to help avoid unnecessary biopsies

US researchers have developed and validated a new urine-based test for prostate cancer, which was shown to meaningfully reduce unnecessary prostate biopsies while providing highly accurate detection.

Photo

News • Personalised oncology

New platform to significantly reduce cancer drug testing and screening time

In a breakthrough for personalised oncology, scientists have developed and demonstrated a novel platform that can significantly reduce the time needed to determine the efficacy of anti-cancer drugs.

Related products

Subscribe to Newsletter